• Users Online: 393
  • Print this page
  • Email this page
CASE REPORT
Year : 2022  |  Volume : 9  |  Issue : 4  |  Page : 149-152

The efficacy of sorafenib after progression on atezolizumab and bevacizumab combination therapy in a patient with advanced hepatocellular carcinoma


Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan

Correspondence Address:
Dr. Yun-Tzu Lin
Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, No. 901, Zhonghua Road, Yongkang, Tainan City 710402
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2311-3006.362637

Rights and Permissions

Sorafenib was approved for the treatment of hepatocellular carcinoma more than 10 years ago; however, the efficacy is limited. The IMbrave150 trial demonstrated better overall survival and progression-free survival with atezolizumab plus bevacizumab combination therapy compared to sorafenib, and so it has become the choice of first-line treatment. However, the optimal choice of subsequent therapy after atezolizumab plus bevacizumab is unknown. We present a case with advanced hepatocellular carcinoma who achieved a complete response for more than 2 years under sorafenib treatment after progression with atezolizumab and bevacizumab combination therapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed484    
    Printed12    
    Emailed0    
    PDF Downloaded56    
    Comments [Add]    

Recommend this journal